Ribon Therapeutics (@RibonTx) / X

Ribon Therapeutics (@RibonTx) / X

Investors – Ribon Therapeutics

Investors – Ribon Therapeutics

A Look Inside Our Culture – Ribon Therapeutics

Heike Keilhack (@haxe73) / X

Ribon Therapeutics (@RibonTx) / X

Fierce Biotech's 2021 Fierce 15

Heike Keilhack (@haxe73) / X

Ribon Therapeutics on X: We've started a PH1 study of RBN-2397, our first-in-class PARP7 inhibitor. PARP7 is a key cancer dependency - helping it evade the immune system. RBN-2397 has demonstrated strong

Ribon Therapeutics (@RibonTx) / X

Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Leadership – Ribon Therapeutics

Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes - Tim J. Wigle, W. David Church, Christina R. Majer, Kerren K. Swinger, Demet Aybar, Laurie B. Schenkel, Melissa M. Vasbinder, Arne

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity - ScienceDirect